Morgan Stanley
NTLA icon

Morgan Stanley’s Intellia Therapeutics NTLA Stock Holding History

Morgan Stanley’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3M Sell
1,731,905
-349,492
-17% -$4.89M ﹤0.01% 2744
2026
Q1 		$26.7M Sell
2,081,397
-246,455
-11% -$3.14M ﹤0.01% 2674
2025
Q4 		$20.9M Sell
2,327,852
-3,694,724
-61% -$50.9M ﹤0.01% 2901
2025
Q3 		$104M Buy
6,022,576
+1,905,715
+46% +$23.5M 0.01% 1374
2025
Q2 		$38.6M Buy
4,116,861
+315,166
+8% +$2.59M ﹤0.01% 2161
2025
Q1 		$27M Sell
3,801,695
-12,851
-0.3% -$130K ﹤0.01% 2386
2024
Q4 		$44.5M Buy
3,814,546
+1,238,512
+48% +$19.3M ﹤0.01% 1936
2024
Q3 		$52.9M Buy
2,576,034
+238,325
+10% +$5.5M ﹤0.01% 1777
2024
Q2 		$52.3M Sell
2,337,709
-307,142
-12% -$7.31M ﹤0.01% 1721
2024
Q1 		$72.8M Buy
2,644,851
+99,829
+4% +$2.77M 0.01% 1421
2023
Q4 		$77.6M Sell
2,545,022
-545,919
-18% -$15.7M 0.01% 1341
2023
Q3 		$97.7M Buy
3,090,941
+241,734
+8% +$9.38M 0.01% 1074
2023
Q2 		$116M Buy
2,849,207
+193,724
+7% +$7.86M 0.01% 998
2023
Q1 		$99M Buy
2,655,483
+137,333
+5% +$5.39M 0.01% 1064
2022
Q4 		$87.9M Buy
2,518,150
+987,599
+65% +$47M 0.01% 1109
2022
Q3 		$85.7M Buy
1,530,551
+294,357
+24% +$18.3M 0.01% 982
2022
Q2 		$64M Sell
1,236,194
-58,805
-5% -$2.99M 0.01% 1206
2022
Q1 		$94.1M Sell
1,294,999
-228,254
-15% -$19.3M 0.01% 900
2021
Q4 		$180M Buy
1,523,253
+377,214
+33% +$47.3M 0.02% 609
2021
Q3 		$154M Buy
1,146,039
+448,316
+64% +$67.9M 0.02% 629
2021
Q2 		$113M Buy
697,723
+192,393
+38% +$15M 0.01% 786
2021
Q1 		$40.6M Sell
505,330
-671,125
-57% -$45M 0.01% 1327
2020
Q4 		$64M Sell
1,176,455
-10,378
-0.9% -$377K 0.01% 928
2020
Q3 		$23.6M Buy
1,186,833
+406,842
+52% +$8.48M ﹤0.01% 1355
2020
Q2 		$16.4M Buy
779,991
+131,139
+20% +$2.23M ﹤0.01% 1557
2020
Q1 		$7.93M Sell
648,852
-303,414
-32% -$4.09M ﹤0.01% 1987
2019
Q4 		$14M Buy
952,266
+29,879
+3% +$416K ﹤0.01% 2031
2019
Q3 		$12.3M Buy
922,387
+33,126
+4% +$528K ﹤0.01% 1916
2019
Q2 		$14.6M Sell
889,261
-1,075,202
-55% -$16.9M ﹤0.01% 1774
2019
Q1 		$33.6M Sell
1,964,463
-267,783
-12% -$3.99M 0.01% 1072
2018
Q4 		$30.5M Buy
2,232,246
+262,189
+13% +$4.87M 0.01% 1117
2018
Q3 		$56.4M Sell
1,970,057
-264,242
-12% -$7.69M 0.01% 888
2018
Q2 		$61.1M Buy
2,234,299
+324,280
+17% +$7.86M 0.02% 804
2018
Q1 		$40.3M Buy
1,910,019
+1,581,092
+481% +$38.9M 0.01% 1057
2017
Q4 		$6.32M Buy
328,927
+39,559
+14% +$913K ﹤0.01% 2835
2017
Q3 		$7.19M Buy
289,368
+43,959
+18% +$828K ﹤0.01% 2597
2017
Q2 		$3.93M Buy
245,409
+33,884
+16% +$473K ﹤0.01% 3130
2017
Q1 		$2.98M Sell
211,525
-33,955
-14% -$456K ﹤0.01% 3440
2016
Q4 		$3.22M Sell
245,480
-37,346
-13% -$561K ﹤0.01% 3442
2016
Q3 		$4.81M Sell
282,826
-18,532
-6% -$359K ﹤0.01% 2689
2016
Q2 		$6.43M Buy
+301,358
New +$8.02M ﹤0.01% 2372

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Morgan Stanley's NTLA Position: Q2 2026 in Review

Morgan Stanley reduced its Intellia Therapeutics (NTLA) stake by 17% in Q2 2026, selling an estimated $4.89M and leaving 1,731,905 shares worth $29.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Morgan Stanley first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. The position peaked at $180M in Q4 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Morgan Stanley held 1,731,905 shares of Intellia Therapeutics worth $29.3M as of Q2 2026.
  • Morgan Stanley sold 349,492 Intellia Therapeutics shares in Q2 2026, an estimated $4.89M.
  • Intellia Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2744 holding.
  • Morgan Stanley first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
  • Morgan Stanley's Intellia Therapeutics position peaked at $180M in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.